Esperion Therapeutics to Present at the Barclays Global Healthcare Conference
March 09 2016 - 7:46PM
Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company
focused on developing and commercializing first-in-class, oral,
low-density lipoprotein cholesterol (LDL-C) lowering therapies for
the treatment of patients with elevated LDL-C, today announced Tim
M. Mayleben, president and chief executive officer, will present at
the Barclays Global Healthcare Conference in Miami, FL on Tuesday,
March 15, 2016 at 8:30 A.M. Eastern Time.
Esperion's Commitment to Cardiometabolic
Disease
Esperion is committed to improving the lives of
patients by developing therapies to lower elevated LDL-C. Esperion
scientists discovered bempedoic acid and the LDL-C lowering therapy
is in late stage development. Esperion plans to develop both
bempedoic acid and a fixed-dose combination of bempedoic acid and
ezetimibe with a particular focus on patients with elevated LDL-C
who are considered intolerant of statin therapy. It is estimated
that approximately 10% of patients who are prescribed statins, 3.5
million patients in the U.S., are considered statin intolerant.
About Esperion
Therapeutics
Esperion Therapeutics, Inc. is a
pharmaceutical company focused on developing and commercializing
first-in-class, oral, LDL-C lowering therapies for the treatment of
patients with elevated LDL-C. Bempedoic acid, the Company’s lead
product candidate, is an inhibitor of ATP Citrate Lyase, a
well-characterized enzyme on the cholesterol biosynthesis pathway.
Bempedoic acid inhibits cholesterol synthesis in the liver,
decreases intracellular cholesterol and up-regulates LDL-receptors,
resulting in increased LDL-C clearance and reduced plasma levels of
LDL-C. For more information, please
visit www.esperion.com and follow us on Twitter
at https://twitter.com/EsperionInc.
Media Contact:
Elliot Fox
W2O Group
212.257.6724
efox@w2ogroup.com
Investor Contact:
Mindy Lowe
Esperion Therapeutics
734.887.3903
mlowe@esperion.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024